30 results about "Cell regulation" patented technology

The invention discloses an environment-emotion gradient association memristive neural network circuit based on a TAP cell regulation mechanism. The environment-emotion gradient association memristive neural network circuit is composed of a hippocampus module and an amygdala kernel module. The hippocampus module comprises an environment recognition neuron module and an emotion generation neuron module; the environment recognition neuron module and the emotion generation neuron module are each composed of a weight regulation and control module adj based on a TAP cell regulation mechanism, an adder, a memristor, a resistor, an operational amplifier, a function module ABM1 and a sampling holder. Wherein the weight regulation and control module adj is composed of a voltage-controlled switch, a summator, a function module ABM2 and a function module ABM3. The almond kernel module is composed of a weight regulation and control module adj, a memristor, a resistor, an operational amplifier and a sampling holder. The provided circuit simulates the hippocampus and amygdala nucleus of the brain in structure, the regulation principle of TAP cells on neural stem cells is used for reference in a weight regulation mechanism, and bidirectional gradient associated memory of the environment and the emotion can be achieved.

The invention discloses a method for producing MK-7 through whole-cell regulation and control by using different time sequence type promoters, recombinant escherichia coli and application. According to the method, the time sequence type promoters are used for regulating and controlling expression of different key genes related to MK-7 synthesis. According to the invention, the time sequence promoter is used for whole-cell regulation and control to produce the vitamin MK-7 for the first time, dynamic regulation of the MK-7 is realized, and the production efficiency of the MK-7 can be remarkably improved by accurately regulating and controlling expression of key genes in a synthesis route of the MK-7 and optimizing an intracellular metabolic process. The promoter disclosed by the invention can regulate cell metabolism and enhance synthesis of MK-7 in different growth stages or under different environmental conditions by controlling the time and strength of gene expression. The MK-7 is produced by adopting the constructed recombinant escherichia coli obtained based on whole-cell regulation of the sequential promoter, and the yield of 14 g / L can be finally achieved in a 5L fermentation tank.

The present invention provides a dual DNA tetrahedron structure, a preparation method and an application thereof. The dual DNA tetrahedron of the present invention includes a first DNA tetrahedron structure, a second DNA tetrahedron structure and a connecting chain. This structure can specifically recognize two cell surface proteins and be labeled by fluorescence; at the same time, due to the steric hindrance effect of the structure, it is difficult for the two proteins to approach each other, affecting the interaction between the two. This structure can exist on the cell surface for a long time, thus having a good cell regulation effect on these two cell membrane surface proteins, specifically reflected in reducing the phosphorylation level of HER2 protein, promoting the expression of apoptosis-related proteins, and ultimately leading to apoptosis of tumor cells and reducing the cell activity of tumor cells.

This document discloses compositions for use with engineered human cells, the compositions comprising a cell regulator or a carrier encoding a cell regulator. This document describes compositions comprising engineered cells, wherein the engineered cells are engineered human cells and contain modifications that make the engineered cells more resistant to alkylating drugs or nucleoside analogs compared to non-engineered human cells. Various methods for treating diseases are provided, including methods for treating cancer in a subject by administering cell regulators and / or engineered cells as therapeutic agents.

The present invention relates to a CRISPR-CAS system for targeting myeloid cell gene editing and a construction method thereof. This scheme uses molecular biological technology to replace the promoter of the Cas9 nuclease in the CRISPR / Cas9 system with a chimeric promoter specifically recognized by myeloid cells, so that the Cas9 nuclease with cutting function is only expressed in myeloid cells; and guide RNA is designed to construct a CRISPR / Cas9 plasmid targeting the target gene, which is then packaged and produced by lentiviral transfection. This scheme can be used to study the role of different genes in myeloid cells regulating the tumor microenvironment.

A bispecific antibody, including: a first antibody or antigen-binding fragment thereof that specifically binds to a first antigen; a second antibody or antigen-binding fragment thereof that specifically binds to a second antigen; where the first antigen is TNFR2, and the second antigen is 4-1BB; or, the first antigen is 4-1BB, and the second antigen is TNFR2. The bispecific antibody is a T cell regulator of the tumor microenvironment, which can stimulate the proliferation of CD8+T cells, activate CD8+T cells, and release anti-tumor factors, such as IFNγ and IL2 by using a TNFR2 agonistic antibody, or can block TNF-TNFR2 and inhibit the proliferation of Treg by using a TNFR2 antagonistic antibody. The bispecific antibody can simultaneously target 4-1BB, activate the 4-1BB signaling pathway of T cells and NK cells, enhance the killing power of cytotoxic T cells and NK cells, and produce anti-tumor activity.

To provide a t-cell regulatory multimer polypeptide effective for regulating the activity of a T-cell and for regulating immune response in an individual, a method for producing the polypeptide, and a pharmaceutical composition including the T-cell regulatory multimer polypeptide.SOLUTION: Provided is a T-cell regulatory multimer polypeptide that includes an immunoregulatory polypeptide and also includes an epitope-presenting Wilms tumor peptide.SELECTED DRAWING: Figure 1A

The present disclosure provides a method comprising: contacting a CD25 positive cell with either a multispecific or a monospecific CD25 binding protein. The multispecific binding protein can comprise: a) a first cell surface binding moiety that specifically binds to CD25 on the surface of the CD25 positive cell, wherein the first cell surface binding moiety comprises at least one immunoglobulin domain or an antigen binding fragment thereof; and b) a second binding moiety that is operatively linked to the first cell surface binding moiety and that specifically binds to the target protein, wherein specific binding of the multispecific binding protein to the CD25 facilitates the internalization of the target protein into the CD25 positive cell. The internalization results in lysosomal degradation of the target protein. A monospecific CD25 binding protein can comprise at least one ISVD that specifically binds to a CD25 (CD25 ISVD) on the surface of a CD25 positive cell and can be utilized in a multispecific CD25 binding protein. The binding of the monospecific CD25 binding protein can modulate cell regulation, e.g., resulting in inactivation of T cells. The present disclosure also provides multispecific and monospecific binding protein compositions, host cells for making the multispecific and monospecific binding protein compositions, and methods of using the multispecific and monospecific binding protein compositions to treat disease.

The invention relates to an up-conversion nanoparticle compound, a preparation method thereof and a cell regulation substrate, the up-conversion nanoparticle compound comprises up-conversion nanoparticles, connecting molecules connected to the surfaces of the up-conversion nanoparticles, and light-operated isomeric molecules reversibly connected with the connecting molecules, rGD polypeptide is connected to the light-controlled isomeric molecule; wherein the upconversion nano-particles can convert near-infrared light irradiated on the upconversion nano-particles into ultraviolet light, and after the light-operated isomeric molecules connected with the RGD polypeptide are radiated by the ultraviolet light, the light-operated isomeric molecules and the RGD polypeptide fall off from the connecting molecules together. The up-conversion nanoparticle compound can be applied to a carrier for cell growth, and is irradiated by near-red light in the cell growth process to dynamically regulate and control cell adhesion, extension and differentiation.

Methods, systems, and compositions of matter for detection, analysis and treatment of biological, chemical and radiation exposure using artificial intelligence-based systems including fuzzy logical and / or machine learning. A system capable of compiling physical, biochemical, hematological, psychological and neural datapoints, analyzing said data points and creating actionable therapeutic interventions in a graded manner based on invasiveness and probability of success. Optimized biological intervention to chemical, radiation and biochemical threats using stem cells, T regulatory cells and induced pluripotent stem cells.

This invention relates to the field of cell regulation technology and discloses a multi-parameter feedback-based intelligent regulation method for Chir99021-induced differentiation of dental pulp stem cells. The method includes: acquiring a dataset of the differentiation process of dental pulp stem cells and performing structured analysis to obtain a multi-parameter monitoring dataset; performing multi-dimensional assessment of cell differentiation status to obtain a differentiation status assessment characterization; obtaining drug release regulation parameters based on the differentiation status assessment characterization and historical differentiation trend data; performing multi-dimensional planning on the differentiation status assessment characterization and drug release regulation parameters to obtain a regulation strategy, and encoding and reconstructing the regulation strategy to obtain microenvironment regulation instructions; applying the microenvironment regulation instructions to obtain an optimized culture microenvironment and monitoring cell state information in the optimized culture microenvironment; and iteratively regulating the drug release regulation parameters based on the cell state information to obtain the final regulation instructions. This invention can improve the accuracy of Chir99021-induced differentiation regulation of dental pulp stem cells.

Compositions of matter, interventions and protocols for treatment of degenerative disc disease through administration of B regulatory cells and / or stimulation of B regulatory cell generation. B regulatory cells can be administered intradiscally in order to support regenerative processes of endogenous nucleus pulposus cells or administered regenerative cells. Peri-spinal administration of B regulatory cells can alter the microenvironment to support activity of therapeutic cells capable of increasing extracellular matrix quality and quantity. B regulatory cells can be expanded in vitro from progenitor cells including induced pluripotent stem cells, or may be utilized from adult progenitor sources such as peripheral blood, cord blood, and bone marrow.

The invention discloses a multi-organ regulation and control combined nano preparation and application thereof, and belongs to the technical field of medicines. The combined nano preparation consists of a nano preparation A and a nano preparation B, the nano preparation A is a parenchymal hepatic cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-Glactase and a THR-beta agonist; and the nano preparation B is an adipose cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-CKGGRAKDC and a PPAR gamma agonist. According to the invention, malignant crosstalk formed by liver-adipose tissue axes is utilized for the first time, and a strategy for treating fatty hepatitis and hepatic fibrosis related to metabolic dysfunction by cooperatively regulating lipid metabolism balance between two organs of liver and fat by using two types of liposomes is innovatively provided; the invention provides a new strategy and way for treating metabolic liver diseases.

Compositions and methods for non-genotoxic monoclonal antibody (mAb) conditioning, where the methods involve altering a cluster of differentiation 117 (CD117; c-KIT) polynucleotide sequence in a hematopoietic stem cell (HSC) or progenitor thereof to encode a CD117 polypeptide with reduced binding to the antibody. In various embodiments, the methods further include introducing a therapeutic alteration to a gene of the HSC or progenitor thereof for treatment of a hemoglobinopathy.

An object of the present invention is to provide a cyclic peptide or a salt thereof and a cyclic peptide complex or a salt thereof, which have excellent binding affinity to an FGFR protein, and to provide a culture medium composition, a material for purification, a material for labeling, a material for cell regulation, and a material for accumulation, which use the cyclic peptide or a salt thereof and the cyclic peptide complex or a salt thereof.According to the present invention, there is provided a cyclic peptide or a salt thereof, the cyclic peptide being a peptide having an amino acid sequence represented by X1-Xm-X2-Xn-X3, in which the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding, and the cyclized portion includes a structure represented by Formula (2),X1 represents a glutamine residue or a histidine residue, Xm represents a peptide residue containing any 2 to 4 amino acid residues, X2 represents an alanine residue, a leucine residue, an isoleucine residue, a phenylalanine residue, a tyrosine residue, a tryptophan residue, a glutamine residue, a serine residue, a threonine residue, an asparagine residue, a glutamic acid residue, an arginine residue, or a histidine residue, Xn represents an amino acid residue or a peptide residue containing any 1 to 3 amino acid residues, and X3 represents an amino acid residue containing an aromatic residue on a side chain, in Formula (2), Z1 and Z2 each independently represent a linking group, and m represents an integer of 1 to 10.

The invention discloses a system and a method for realizing cell regulation and control based on luminous oscillation stimulation of cell nucleuses, and relates to the technical field of crossing of biotechnology and optical micro-control. The method comprises the following steps: internalizing biocompatible microspheres beside a living cell nucleus, capturing the microspheres by using an optical tweezers module, and driving a light potential well to carry out double-position high-speed alternate switching by using a parameter control unit, so as to construct a programmable optical mechanical oscillator to apply oscillation stimulation to cells in a set direction, frequency and amplitude. According to the invention, the limitation of the traditional method is broken through, and direct and controllable mechanical stimulation and observation on the cell nucleus in the living cell are realized.

The invention discloses a photo-thermal temperature-sensitive cell membrane drug delivery system capable of controlling drug release as well as a preparation method and application of the photo-thermal temperature-sensitive cell membrane drug delivery system. The delivery system comprises a cell membrane carrier, and temperature-sensitive lipid and a photosensitizer are doped in the cell membrane carrier. According to the scheme, the thermo-sensitive lipid and the photosensitizer are ingeniously introduced into a cell membrane delivery system at the same time, photo-thermal controllable drug depolymerization and release after target tissue arrives are achieved, then the drug is accurately delivered to heterotarget cells, and the treatment effects of disease tissue targeting and multi-cell regulation are achieved. The design obviously exceeds the limitation of a traditional cell membrane nano-drug delivery system, the traditional cell membrane nano-drug delivery system is only limited to targeting of a single cell type, and the action range is relatively limited.

This invention relates to the preparation and application of an antitumor vaccine based on a conjugate of monophosphate ester A (MPLA) and tumor-associated glycoantigen STn, belonging to the field of antitumor glycoantigen vaccine development technology. The antitumor vaccine of this invention can be prepared by chemical methods, possessing the advantages of a well-defined structure, clear composition, and no need for adjuvants. Furthermore, the antitumor vaccine of this invention can induce a stronger immune response against the glycoantigen STn, generating a T-cell-regulated immune response with higher titers, higher affinity, and memory, thereby achieving the purpose of specifically killing tumor cells.

The invention relates to a strong-field terahertz cell irradiator, belongs to the field of terahertz biological state regulation and control and the field of experimental technical equipment, and solves the technical problems that a cell regulation and control system based on a strong-field terahertz radiation source does not exist in the prior art and the existing system does not have a portable and movable function. The strong-field terahertz cell irradiator comprises a mounting platform, a strong-field terahertz source module and a cell irradiation module. The system is portable and movable, and is suitable for diversified scenes. The system is high in integration level, the average power of the terahertz waves is high, the monopulse terahertz energy is high, the energy of the terahertz waves irradiated on the biological substances is ensured, the high field intensity enables the terahertz waves to generate a regulation effect with the biological substances more easily, and the state regulation of the strong-field terahertz waves on the biological substances can be better researched.

An object of the present invention is to provide a cyclic peptide or a salt thereof and a cyclic peptide complex or a salt thereof, which have excellent binding affinity to an FGFR protein and excellent stability, and to provide a culture medium composition, a material for purification, a material for labeling, a material for cell regulation, and a material for accumulation, which use the cyclic peptide or a salt thereof and the cyclic peptide complex or a salt thereof.A cyclic peptide or a salt thereof, the cyclic peptide being a peptide having an amino acid sequence represented by X1-X2-X3-X4, in which the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding, and the cyclized portion includes a structure represented by Formula (2),X1 represents an alanine residue, a leucine residue, an isoleucine residue, a valine residue, a phenylalanine residue, a tyrosine residue, or a threonine residue, X2 represents an amino acid residue having an aromatic residue on a side chain, X3 represents any amino acid residue, and X4 represents an alanine residue, a glycine residue, a phenylalanine residue, a tyrosine residue, a tryptophan residue, a serine residue, or a histidine residue, in Formula (2), Z1 and Z2 each independently represent a linking group, and m represents an integer of 1 to 10.

The application provides a system for on-demand regulation of cell behavior based on host-guest recognition space reversible rearrangement of cell receptors and application thereof, and the system comprises a beta-cyclodextrin polymer, a Met binding nucleic acid aptamer labeled with ferrocene and adamantane. Linear beta-cyclodextrin polymer and cross-linked beta-cyclodextrin polymer are used in the system. The two kinds of beta-cyclodextrin polymers have different regulation effects on cell receptors. The system composed of linear beta-cyclodextrin polymer can sensitively rearrange Met receptors to significantly inhibit HGF-induced Met receptor activation, block related signal pathways and indirectly regulate cell behavior. The system composed of cross-linked beta-cyclodextrin polymer can activate cell receptors and directly regulate cell behavior. The system can be applied to preparation of a detection kit for cell analysis and preparation of a drug for cell regulation to regulate the phosphorylation level of Met receptors, cell proliferation and cell migration behavior on demand.

The application relates to the technical field of biomaterials, in particular to a stem cell aggregate-derived decellular extracellular matrix and application thereof in bone defect repair. The decellular extracellular matrix is formed by subjecting a 3D cell aggregate in the form of a sphere to decellularization treatment, and the 3D cell aggregate is induced to form by transferring adult bone marrow mesenchymal stem cells after culture to a low-absorption cell culture carrier. The 3D dECM has a complete three-dimensional scaffold structure and abundant pores, while retaining key extracellular matrix components such as collagen, fibronectin and laminin, and is closer to the in-vivo tissue microenvironment; the 3D dECM significantly enhances the migration ability of cells, effectively improves the stemness of BMSCs, promotes extracellular matrix synthesis, and improves the mitochondrial function of BMSCs, has excellent cell regulation ability and functional activity, and thus solves the problems of low bioactivity and insufficient bionics of traditional 2D dECM.

An object of the present invention is to provide a cyclic peptide or a salt thereof and a cyclic peptide complex or a salt thereof, which have excellent binding affinity to an FGFR protein and excellent stability, and to provide a culture medium composition, a material for purification, a material for labeling, a material for cell regulation, and a material for accumulation, which use the cyclic peptide or a salt thereof and the cyclic peptide complex or a salt thereof.A cyclic peptide or a salt thereof, the cyclic peptide being a peptide having an amino acid sequence represented by X1-Xn-X2-X3-X4, in which the cyclic peptide contains a cyclized portion that is cyclized via covalent bonding, and the cyclized portion includes a structure represented by Formula (2),X1 represents an alanine residue, a proline residue, a leucine residue, an isoleucine residue, a valine residue, a phenylalanine residue, a tyrosine residue, a tryptophan residue, an asparagine residue, a serine residue, an arginine residue, a histidine residue, or a methionine residue, Xn represents a peptide residue containing any 1 to 7 amino acid residues, X2 represents an alanine residue, a glycine residue, a leucine residue, an isoleucine residue, or a valine residue, X3 represents any amino acid residue, and X4 represents an amino acid residue having an aromatic residue on a side chain, in Formula (2), Z1 and Z2 each independently represent a linking group, and m represents an integer of 1 to 10.

Main claim: The nesting material (Fig. 1) 1, consisting of a binder preferably based on lignin or polylactic acid or plant starch with the addition of cell regulators, hardeners, and blowing agents, and with the addition of natural materials such as loam, sand, clay, and plant fibers, is characterized by having a brittle, rigid foam-like consistency, by being able to have milled channels and a milled channel system, and by being environmentally friendly, ecological, recyclable, and compostable, and by being inserted into a transparent container (Fig. 1) 2 (e.g., made of glass, plastic, etc.) that is open on at least one side and is oriented vertically or horizontally and has the shape of a cuboid (or another geometric shape, e.g., a cylinder, etc.). The container (Fig. 1) 2 has one or more access points.

The invention discloses a cell regulator preparation method, which comprises: 1, preparing a plant extraction liquid, adding water to bamboo reed, crushing, and filtering residue to obtain the plant extraction liquid; step 2, adding elements, namely adding calcium iron zinc selenium tablets into the plant extracting solution prepared in the step 1, and uniformly stirring after the calcium iron zinc selenium tablets are melted to obtain a semi-finished product, and the weight ratio of the bamboo reed to the calcium iron zinc selenium tablets is 250: 9; and step 3, drying: performing low-temperature drying on the semi-finished product obtained in the step 2 to obtain final powder. The cell regulator can peel off residual heavy metals in agricultural products such as rice, corn, soybeans, wheat, fruits, nuts, Chinese prickly ash, vegetables, tea leaves and the like, and is used in a plant growth cycle, so that the heavy metal elements in the plants are metabolized out in the growth process of the plants, and the purpose of removing the residual heavy metals in the plants is achieved.

Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and methods may increase the expression or protein level of a transcription factor selected from TGIF2LX, TGIF1, TGIF2, FOS, HNF4A, KLF8, NFKBIZ, CARF, EBF3, HMX3, LHX4, LMX1A, PLAG1, PLAGL1, POU2F3, SOX14, TFAP2D, and WT1, or a combination thereof. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.

Methods for enhancing CAR-T or CAR-M cell activity by modulating (e.g., activating or inhibiting) cytotoxic activity of the CAR cells over time to speed up or delay killing activity of the cells. Enhanced CAR-T or CAR-M cells prepared according to methods. Therapeutic compositions and treatment methods, such as for treating cancers, using the enhanced CAR-T or CAR-M cells. The enhanced CAR-T or CAR-M cells comprise drug-loaded nanoparticles or nanocarriers comprising a cell-penetrating peptide (WTAS or rp-182) or a fragment thereof and a modified poly(P-amino ester) (PBAE) polymer associated or assembled with one or more cell modulating agents. The cell modulating agents are released into the cytoplasm to thereby modulate the activity of the enhanced CAR-T cells or CAR-M cells.

The application discloses a kind of autotrophic denitrification multi-cell regulation device and sewage denitrification method, the multi-cell regulation device includes multiple autotrophic denitrification pools in box (1), clear water pool (2), pipeline (3) and equipment room (7), autotrophic denitrification pool is installed in the box by parallel mode between each other, the denitrification process of each autotrophic denitrification pool is independent of each other, each has independently inlet and outlet pipe, each inlet and outlet pipe is connected with PLC controller, so that autotrophic denitrification pool can be automatically regulated according to sewage treatment capacity, while the number of autotrophic denitrification pool can be adjusted according to the temperature of sewage to be treated, give the device stronger sewage treatment adaptability, reduce sewage treatment cost, while improve denitrification effect and denitrification efficiency, with good application prospect.

The present disclosure provides modified natural killer cells having natural killer (NK) cell function and dendritic cell function, and a method for culturing the same. By administering the modified natural killer cells, cell-regulated immunization can effectively inhibit cancer cells in a subject.

The invention provides a system for on-demand regulation and control of cell behaviors based on subject-object recognition of spatial reversible rearrangement cell receptors and application of the system. The system comprises a beta-cyclodextrin polymer, a ferrocene-labeled Met binding nucleic acid aptamer and adamantane. Linear beta-cyclodextrin polymers and cross-linked beta-cyclodextrin polymers are used in the system of the invention. The two beta-cyclodextrin polymers have different regulation and control effects on cell receptors, and a system formed by the linear beta-cyclodextrin polymers can sensitively rearrange the Met receptors, so that HGF-induced Met receptor activation is obviously inhibited, related signal channels are blocked, and cell behaviors are indirectly regulated. A system formed by the cross-linked beta-cyclodextrin polymer can activate a cell receptor and directly regulate cell behaviors. The system disclosed by the invention can be applied to preparation of a detection kit for cell analysis and preparation of a medicine for cell regulation and control so as to regulate the phosphorylation level, cell proliferation and cell migration behaviors of the Met receptor as required.